Lenalidomide Plus Rituximab Chemotherapy for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas


( Last Updated : November 22, 2021)
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1392-000

Details


Question

  1. What is the clinical effectiveness of lenalidomide plus rituximab combination chemotherapy (R2) for relapsed or refractory indolent B-cell non-Hodgkin lymphomas?
  2. What is the cost-effectiveness of lenalidomide plus rituximab combination chemotherapy (R2) for relapsed or refractory indolent B-cell non-Hodgkin lymphomas?

Key Message

Data from 2 randomized controlled trials indicated a statistically significant benefit in progression-free survival and overall survival for patients with follicular lymphoma who received R2 as compared to patients who received rituximab plus placebo or R-CHOP.

The frequency of all types of adverse events in patients receiving R2 as compared to rituximab plus placebo or R-CHOP was comparable, but patients receiving R2 experienced more severe adverse events.

Two economic analyses concluded that R2 was cost-effective for the treatment of patients with follicular lymphoma as compared to rituximab plus placebo (UK and Dutch contexts).

Evidence identified in this review was mostly limited to that describing patients with follicular lymphoma.

Most evidence identified in this review was generated with support and/or funding from a private industry pharmaceutical manufacturer.